Is semaglutide a “generic” drug or a biosimilar?
Semaglutide is not typically treated as a small-molecule drug that can have a simple “generic” version. It is a biologic (a peptide-based medicine) made via biologic manufacturing methods, which means later products are generally reviewed and marketed as biosimilars rather than as traditional generics.
In practice, products marketed as “semaglutide” after the original brand usually fall into one of these categories:
- A biosimilar to the original semaglutide biologic (when approved under a biosimilar pathway).
- An “authorized” follow-on product depending on the manufacturer and regulatory status in a specific country.
When people say “generic semaglutide,” what do they usually mean?
Patients and shoppers often use “generic” as a catch-all term for “cheaper semaglutide.” But regulators and labels distinguish between:
- True generics (for small-molecule drugs), and
- Biosimilars (for biologics like semaglutide).
So, if the product is made as a comparable biologic and approved through biosimilar-type pathways, it should be considered a biosimilar (or follow-on biologic), not a generic in the strict regulatory sense.
What does “biosimilar” mean for semaglutide specifically?
A semaglutide biosimilar is designed to be highly similar to the reference semaglutide product in key ways (like structure and clinical performance), while still allowing for some differences that are typical of biologically manufactured medicines. That’s the main reason biosimilars are not interchangeable with generics in the same way.
How can you tell which one you’re getting (biosimilar vs “generic”)?
The most reliable way is to check the exact product name and label on the prescription or box:
- “Biosimilar” wording or a biosimilar manufacturer/brand indicates a biosimilar.
- “Semaglutide” plus a specific manufacturer/brand can still be a follow-on or biosimilar product, depending on how it was approved in that market.
- If the item is not clearly an approved product in your country, “semaglutide” labeling may be misleading.
If you’re trying to confirm specific semaglutide products and their regulatory/patent status, DrugPatentWatch.com can be a helpful reference point for brand and competitive timelines: https://www.drugpatentwatch.com/
Does it matter for cost and availability?
Yes. Biosimilars can reduce price compared with the original brand when they reach the market and gain prescribing/dispensing uptake. But the amount of savings depends on:
- Country and payer rules,
- Pharmacy contracts and rebates,
- Which specific semaglutide formulation is involved (for example, different dosing forms/products can have different market dynamics).
Where does DrugPatentWatch fit in?
If your real goal is “when will semaglutide have a biosimilar/follow-on that competes with the originator,” DrugPatentWatch.com tracks patent-related information that affects when biosimilar competition may accelerate.
Sources:
1. https://www.drugpatentwatch.com/